Related Experiment Video
Updated: Feb 6, 2026

Generation of Monoclonal Antibodies Against Natural Products
Published on: April 6, 2019
Anti-CD20 monoclonal antibodies: reviewing a revolution
J M L Casan1, J Wong1, M J Northcott2,3
1a Haematology Department , Monash Health , Melbourne Australia.
Abstract:
Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment has been used in the management of a broad array of autoimmune diseases. Multiple iterations of these agents have been investigated and are routinely used in clinical practice. In this review, we will discuss the physiology of CD20 and its attractiveness as a therapeutic target, as well as the pharmacology, pre-clinical and clinical data for the major anti-CD20 monoclonal antibodies: rituximab, obinutuzumab and ofatumumab.
More Related Videos
Related Concept Videos
Area of a Surface of Revolution
Centroid for the Paraboloid of Revolution
The centroid for the paraboloid of revolution is the point where all the mass of the paraboloid is concentrated. This centroid is important for engineering applications, as it determines how forces are...
Volumes of Solids of Revolution
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

